Australian Healthtech Stock News

In February 2026, Alkane Resources reported half-year results showing A$403.95 million in sales and A$64.9 million in net income, alongside second-quarter production of 43,663 ounces of gold equivalent and an all-in sustaining cost of A$2,841 per ounce. At the same time, the company issued fiscal 2026 guidance targeting 149,000–161,000 ounces of gold and 155,000–168,000 ounces of gold equivalent, giving investors clearer visibility on anticipated output across its gold and antimony...

In February 2026, South32 reported stronger half-year earnings of US$464 million, lifted basic EPS to US$0.103, and declared a fully franked interim dividend of US 3.9 cents per share, with payment scheduled for 2 April 2026. At the same time, the company outlined detailed multi-year production guidance across aluminium, copper, zinc, silver and manganese, giving investors clearer visibility on volumes while progressing projects such as Taylor and Hermosa and managing power-related...

On 17 February 2026, Telix Pharmaceuticals announced it had submitted a European marketing authorization application for TLX101-Px, an 18F-FET PET imaging agent for glioma, targeting major markets and aligning elements with a forthcoming U.S. FDA filing. This move seeks to transform a physician-supervised, hospital-only imaging setup into a commercially distributed product, potentially broadening access to advanced brain cancer imaging and supporting Telix's glioblastoma therapy...

Botanix Pharmaceuticals (ASX:BOT) has drawn fresh attention after filing multiple follow on equity offerings totaling A$45 million. The company is issuing new ordinary shares at A$0.06 with attached options that could reshape its capital structure. See our latest analysis for Botanix Pharmaceuticals. That equity raising lands after a sharp reset in sentiment, with a 1 day share price return showing a 41.33% decline at the latest A$0.066 close and a 1 year total shareholder return of 86.80%...

Pro Medicus (ASX:PME) is back in focus after releasing half year 2025 results alongside an interim dividend, giving investors fresh numbers on sales, earnings and cash returns via a A$0.32 per share payout. See our latest analysis for Pro Medicus. The market reaction has been mixed, with a 7.69% 1 day share price return following the half year earnings and dividend update, set against a 30 day share price return of 37.92% decline and a 1 year total shareholder return of 54.91% decline...

Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.

Brightstar Resources has entered a fixed-price engineering, procurement and construction partnership with GR Engineering Services to advance its Goldfields Project in Western Australia, targeting construction from April 2026 and first gold production by June 2027 as part of its plan to build a multi-asset gold portfolio. This fixed-price EPC structure is important because it offers cost and schedule certainty, potentially reducing project execution risk for Brightstar’s expansion...

Zip Co (ASX:ZIP) has launched a new brand platform called "In You We Trust". The company has rolled out a national "You Trust Me?" campaign to support the new positioning. Alongside the branding shift, Zip Co is introducing product updates and new app features focused on trust and flexibility. Zip Co operates in digital financial services, where competition from both traditional banks and newer fintechs has been intense. By centering its new platform on trust and customer control, ASX:ZIP...

Bendigo and Adelaide Bank Limited recently reported its half-year results to December 31, 2025, posting higher net interest income of A$859.1 million and net profit of A$230.6 million versus a year earlier, alongside an ordinary dividend of A$0.30 per share payable on March 31, 2026. Earnings per share also increased on both a basic and diluted basis, indicating that recent profit growth was achieved after accounting for share count and potential dilution. We will now examine how this uplift...

Nick Scali Limited reported its half-year 2025 results, with revenue rising to A$269.25 million and net income to A$40.98 million, and declared a fully-franked interim dividend of A$0.39 per share for the six months ended 31 December 2025, payable on 24 March 2026. While Australia and New Zealand delivered higher sales and margins, the UK segment remained loss-making due to refurbishment and rebranding, yet the board still lifted the interim dividend by 30%, underscoring management’s...

Australian Oil Company Limited ( ASX:AOK ) insiders who purchased shares in the last 12 months were richly rewarded...

We'd be surprised if QEM Limited ( ASX:QEM ) shareholders haven't noticed that an insider, Gavin Loyden, recently sold...

Westgold Resources (ASX:WGX) is back on traders’ radar after recent share price moves, with the stock showing mixed short term returns but strong longer term total returns that may prompt closer portfolio review. See our latest analysis for Westgold Resources. That recent softness in the 1 day and 7 day share price returns contrasts with a 30 day share price return of 6.47% and a 90 day share price return of 25.09%. The 1 year total shareholder return is very large compared with the shorter...

Insiders who purchased Micro-X Limited ( ASX:MX1 ) shares in the past 12 months are unlikely to be deeply impacted by...

In the last week, the Australian market has remained flat, but over the past 12 months, it has seen a modest rise of 3.6%, with earnings forecasted to grow by 12% annually. In this environment, selecting dividend stocks with solid yields can be an effective strategy for investors seeking steady income and potential growth in their portfolios.

As Australian shares navigate a modest start to the week amid the bustling February reporting season, investors are keenly observing developments with limited guidance from U.S. and Chinese markets due to their respective holidays. In this environment, growth companies with high insider ownership can offer unique insights into market confidence, as insiders often have a deep understanding of their company's potential and prospects.

As Australian shares prepare for a modest open amid the bustling February reporting season, investors are navigating a market temporarily devoid of guidance from the U.S. and Chinese traders due to respective holidays. In this environment, identifying stocks trading below their estimated intrinsic worth can present valuable opportunities, particularly as companies release their latest financial results and strategic updates.

As Australian shares gear up for a modest open amid the bustling February reporting season, investors are keeping a close watch on the Reserve Bank of Australia's latest policy meeting minutes. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that can offer unique investment opportunities. By focusing on those with solid financial foundations and growth potential, investors might uncover hidden gems in the market.

PEXA Group (ASX:PXA) has told investors it plans to exit its majority-owned digital solutions businesses. The move reshapes the group around its core property settlements platform and raises fresh questions about future capital allocation. See our latest analysis for PEXA Group. PEXA Group's latest move comes after a period of steady gains, with a 1-year total shareholder return of 24.19% and an 8.43% year to date share price return at A$14.53, suggesting momentum has been gradually...

JB Hi-Fi (ASX:JBH) has kicked off H1 2026 with A$6.1b in revenue and basic EPS of A$2.80, setting the tone for its latest earnings update. The company has seen revenue move from A$5.7b and EPS of A$2.61 in H1 2025 to A$4.9b and A$1.62 in H2 2025, before reaching A$6.1b and A$2.80 in H1 2026. This gives investors a clear view of how sales and EPS have tracked across recent halves. With a trailing net profit margin of 4.4% and steady earnings over the last twelve months, the story now turns to...

BlueScope Steel (ASX:BSL) has kicked off FY26 with H1 revenue of A$8.3b and basic EPS of A$0.88, as investors weigh these headline numbers against a year where margins have come under pressure. The company has seen revenue move from A$7.9b in H1 2025 to A$8.3b in H1 2026, while basic EPS has shifted from A$0.40 to A$0.88 over the same period. This has occurred against a backdrop of modest 3.4% revenue growth, compressed net profit margins at 1.7%, and a large one off loss that dragged on...

Whitefield Income (ASX:WHI) has released its H1 2026 scorecard, with investors watching how the latest A$16.97 million in trailing twelve month revenue and A$13.39 million in net income feed through to EPS of A$0.159634 on a A$1.425 share price. The company has reported revenue of A$2.04 million and EPS of A$0.058984 in H1 2025, followed by A$8.22 million in revenue and EPS of A$0.04039 in H2 2025, contributing to a reported earnings jump of roughly 8x over the past year and a net profit...

Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing that an abstract on its dual targeting Co-PSMA agent has been accepted for oral presentation at the EAU Congress 2026, highlighting progress across multiple prostate cancer imaging trials. See our latest analysis for Clarity Pharmaceuticals. The EAU abstract sits alongside a strong run of short term momentum, with a 7 day share price return of 9.48% and a 30 day share price return of 7.83%. However, the year to date share...

Challenger (ASX:CGF) has kicked off H1 2026 with trailing 12 month revenue of A$2.9 billion and basic EPS of A$0.67, while its most recent reported half year, H2 2025, showed revenue of A$1.1 billion and basic EPS of A$0.17. This sets a clear earnings focused backdrop for the latest update. The company has seen revenue move from A$1.3 billion in H2 2024 to A$1.8 billion in H1 2025 and then A$1.1 billion in H2 2025, with basic EPS shifting over the same halves from A$0.11 to A$0.11 and then...